Efficacy of Sirolimus in Treating Tuberous Sclerosis and Lymphangioleiomyomatosis
Authors:
- Elahna PaulEPElahna Paul
- Elizabeth ThieleETElizabeth Thiele
- 10 January 2008
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 358 (2) , 190-192
Abstract
Owing to their immunosuppressive and antiproliferative effects, sirolimus (also called rapamycin) and related drugs are being evaluated as part of many transplant immunosuppresion regimens, as well as for a plethora of medical conditions such as type 1 diabetes, macular degeneration, coronary artery disease, and metastatic or refractory cancers of the breast, prostate, lung, and liver, to name but a few.The effects of sirolimus are mediated by its inhibition of the curiously named cytoplasmic protein mammalian target of rapamycin (mTOR), a ubiquitous serine–threonine kinase that is intimately involved in the regulation of protein synthesis, cell growth, cytoskeletal organization, and other . . .Keywords
This publication has 11 references indexed in Scilit:
- Sirolimus Therapy in Tuberous Sclerosis or Sporadic LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisNew England Journal of Medicine, 2008
- Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complexEuropean Journal of Internal Medicine, 2007
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- The mTOR Pathway in the Control of Protein SynthesisPhysiology, 2006
- The Tuberous Sclerosis ComplexNew England Journal of Medicine, 2006
- Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis ComplexAmerican Journal of Kidney Diseases, 2006
- Rapamycin causes regression of astrocytomas in tuberous sclerosis complexAnnals of Neurology, 2006
- Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2Nature Neuroscience, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000